Abstract:Middle East respiratory syndrome coronavirus (MERS-CoV) with pandemic potential is a major worldwide threat to public health. However, vaccine development for this pathogen lags behind as immunity associated with protection is currently largely unknown. In this study, an immunoinformatics-driven genome-wide screening strategy of vaccine targets was performed to thoroughly screen the vital and effective dominant immunogens against MERS-CoV. Conservancy and population coverage analysis of the epitopes were done by the Immune Epitope Database. The results showed that the nucleocapsid (N) protein of MERS-CoV might be a better protective immunogen with high conservancy and potential eliciting both neutralizing antibodies and T-cell responses compared with spike (S) protein. Further, the B-cell, helper T-cell and cytotoxic T lymphocyte (CTL) epitopes were screened and mapped to the N protein. A total of 15 linear and 10 conformal B-cell epitopes that may induce protective neutralizing antibodies were obtained. Additionally, a total of 71 peptides with 9-mer core sequence were identified as helper T-cell epitopes, and 34 peptides were identified as CTL epitopes. Based on the maximum HLA binding alleles, top 10 helper T-cell epitopes and CTL epitopes that may elicit protective cellular immune responses against MERS-CoV were selected as MERS vaccine candidates. Population coverage analysis showed that the putative helper T-cell epitopes and CTL epitopes could cover the vast majority of the population in 15 geographic regions considered where vaccine would be employed. The B- and T-cell stimulation potentials of the screened epitopes is to be further validated for their efficient use as vaccines against MERS-CoV. Collectively, this study provides novel vaccine target candidates and may prompt further development of vaccines against MERS-CoV and other emerging infectious diseases.

Middle East Respiratory Syndrome: Current Status and Future Prospects for Vaccine Development

Development of Middle East Respiratory Syndrome Coronavirus vaccines – advances and challenges

Current Advancements and Potential Strategies in the Development of MERS-CoV Vaccines

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

[Current Status of Middle East Respiratory Syndrome Vaccines].

Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies

Antibodies And Vaccines Against Middle East Respiratory Syndrome Coronavirus

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development

Advances in mRNA and other vaccines against MERS-CoV

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Prospects for a MERS-CoV Spike Vaccine

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain

Receptor-binding domain-based subunit vaccines against MERS-CoV.

Evaluation of candidate vaccine approaches for MERS-CoV

[Small Molecular Agents Against MERS-CoV Infection].

Calling for rapid development of a safe and effective MERS vaccine.

From SARS to MERS: Evidence and Speculation

Receptor-binding Domain As a Target for Developing SARS Vaccines.

Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases

Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development

Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice